Pay in 4 interest-free payments of $6.01 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period
Quick Answer: Semaglutide is a GLP-1 receptor agonist showing 14.9% average body weight loss in the STEP 1 trial at 68 weeks
It will win you over with both its ingredients and its refreshing fruity flavour
Multiple clinical trials have demonstrated semaglutide's beneficial effects on markers of insulin sensitivity, though it is important to note that the medication is not specifically FDA-approved for treating insulin resistance as a standalone indication
